These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270 [TBL] [Abstract][Full Text] [Related]
6. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
7. New understanding of immunological mechanisms. Saalmüller A Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965 [TBL] [Abstract][Full Text] [Related]
8. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
9. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264 [TBL] [Abstract][Full Text] [Related]
11. Melanoma cancer vaccines and anti-tumor T cell responses. Vujanovic L; Butterfield LH J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270 [TBL] [Abstract][Full Text] [Related]
12. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973 [TBL] [Abstract][Full Text] [Related]
13. The relevance of cytokines for development of protective immunity and rational design of vaccines. Chabalgoity JA; Baz A; Rial A; Grille S Cytokine Growth Factor Rev; 2007; 18(1-2):195-207. PubMed ID: 17347024 [TBL] [Abstract][Full Text] [Related]
14. Immune responses to human tumors: development of tumor vaccines. Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571 [TBL] [Abstract][Full Text] [Related]
15. Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool. Schultz-Thater E; Frey DM; Margelli D; Raafat N; Feder-Mengus C; Spagnoli GC; Zajac P J Transl Med; 2008 Oct; 6():58. PubMed ID: 18925935 [TBL] [Abstract][Full Text] [Related]
16. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743 [TBL] [Abstract][Full Text] [Related]